The metabolism of phytanic acid and pristanic acid in man: A review

Journal of Inherited Metabolic Disease

Volumn 21, Issue 7, 1998, Pages 697-728

  Verhoeven, N M ^a   Wanders, R J A ^b   Poll The, B T ^c   Saudubray, J M ^d   Jakobs, C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COENZYME A; FATTY ACID; OXYGENASE; PHYTANIC ACID; PRISTANIC ACID; UNCLASSIFIED DRUG;

ENZYME DEFICIENCY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HUMAN; PEROXISOME; REFSUM DISEASE; REVIEW;

ANIMALS; FATTY ACIDS; HUMANS; OXIDATION-REDUCTION; PHYTANIC ACID;

EID: 0031752194     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005476631419     Document Type: Review

References (173)

1. Ackman RG, Hansen RP (1967) The occurrence of diastereomers of phytanic and pristanic acids and their determination by gas-liquid chromatography. Lipids 2: 357-362.
2. Aubourg P, Kremser K, Roland MO, Rocchiccioli F, Singh I (1993) Pseudo infantile Refum's disease: catalase-deficient peroxisomal particles with partial deficiency of plasmalogen synthesis and oxidation of fatty acids. Pediatr Res 34: 270-276.
3. Avigan J (1966) The presence of phytanic acid in normal human and animal plasma. Biochim Biophys Acta 116: 391-394.
4. Avigan J, Steinberg D, Gutman A, Mize CE, Milne GWA (1966) α-Decarboxylation, an important pathway for the degradation of phytanic acid in animals. Biochem Biophys Res Commun 24: 838-844.
5. Balfe A, Hoefler G, Chen WW, Watkins PA (1990) Aberrant subcellular localization of peroxisomal 3-ketoacyl-CoA thiolase in Zellweger syndrome and rhizomelic chondrodysplasia punctata. Pediatr Res 27: 301-310.
6. Barth PG, Wanders RJA, Schutgens RBH, Bleeker-Wagemakers EM, Heemstra D van (1990) Peroxisomal β-oxidation defect with detectable peroxisomes: a case with neonatal onset and progressive course. Eur J Pediatr 149: 722-726.
7. Barth PG, Wanders RJA, Schutgens RBH, Staalman CR (1996) Variant rhizomelic chondrodysplasia punctata (RCDP) with normal plasma phytanic acid: clinicobiochemical delineation of a subtype and complementation studies. Am J Med Genet 62: 164-168.
8. Baumgart E, Vanhooren JCT, Fransen M et al (1996) Molecular characterization of the human peroxisomal branched-chain acyl-CoA oxidase - cDNA cloning, chromosomal assignment, tissue distribution, and evidence for the absence of the protein in Zellweger syndrome. Proc Natl Acad Sci USA 93: 13748-13753.
9. Baumgartner MR, Verhoeven NM, Jakobs C, et al (1998a) Pseudo-Werdnig-Hoffmann disease as presenting symptom in a new peroxisome biogenesis disorder. Neurology, in press.
10. Baumgartner MR, Poll-The BT, Jakobs C, et al (1998b) Clinical approach to inherited peroxisomal disorders. Consecutive series of 27 patients. Ann Neurol, in press.
11. Baxter JH (1968) Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease. J Lipid Res 9: 636-641.
12. Billimoria JD, Gibberd FB, Clemens ME, Whitelaw MN (1982) Metabolism of phytanic acid in Refsum's disease. Lancet i: 1944.
13. Body DR, Hansen RP (1978) The occurrence of C13 to C31 branched-chain fatty acids in the feces of sheep fed rye grass, and of C12 to C34 normal fatty acids in both the feces and the rye grass. J Sci Food Agric 29: 107-114.
14. Bowen P, Lee CSN, Zellweger H (1964) A familial syndrome with multiple congenital defects. Bull Johns Hopkins Hosp 114: 402-414.
15. Braverman N, Steel G, Obie C, et al (1997) Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nature Genetics 15: 369-376.
16. Brenton DP, Krywawych S (1982) 3-Methyladipate excretion in Refsum's disease. Lancet i: 624.
17. Burdette DE, Kremser K, Fink JK, Pahan K, Stanley W, Singh I (1996) Late-onset generalized disorders of peroxisomes. Neurology 46: 829-831.
18. Caruso U, Fowler B, Erceg M, Romano C (1991) Determination of very-long-chain fatty acids in plasma by a simplified gas-chromatography mass spectrometric procedure. J Chromatogr 562: 147-152.
19. Casteels M, Schepers L, Eldere J van Eyssen H, Mannaerts GP (1988) Inhibition of 3α,7α,12α-trihydroxy-5β-cholestanoic acid oxidation and of bile acid secretion in rat liver by fatty acids. J Biol Chem 263: 4654-4661.
20. Chang CC, Lee WH, Moser H, Valle D, Gould SJ (1997) Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders. Nature Genet 15: 385-388.
21. Christensen E, Anker Pedersen S, Leth H, Jakobs C, Schutgens RBH, Wanders RJA (1997) A new peroxisomal β-oxidation disorder in twin neonates : defective oxidation of both cerotic and pristanic acids. J Inher Metab Dis 20: 658-664.
22. Claridge KG, Gibbert FB, Sidey MC (1992) Refsum disease: the presentation and ophthalmic aspects of Refsum disease in a series of 23 patients. Eye 6: 371-375.
23. Clayton PT, Lake BD, Hjelm M et al (1988) Bile and analysis in 'pseudo-Zellweger' syndrome: clues to the defect in peroxisomal β-oxidation. J Inher Metab Dis 11 (supplement 2): 165-168.
24. Clayton PT, Johnson AW, Mills KA, et al (1996) Ataxia associated with increased plasma concentrations of pristanic acid, phytanic acid and C27 bile acids but normal fibroblast branched-chain fatty acid oxidation. J Inher Metab Dis 19: 761-768.
25. 2, cofactor requirements, subcellular localization, and formation of a 2-hydroxy-3-methylacyl-CoA Intermediate. Eur J Biochem 240: 674-683.
26. Croes K, Casteels M, Asselberghs S, Herdewijn P, Mannaerts GP, van Veldhoven PP (1997a) Formation of a 2-methyl-branched fatty aldehyde during peroxisomal α-oxidation. FEBS Lett 412: 643-645.
27. Croes K, Veldhoven PP van, Mannaerts GP, Casteels M (1997b) Production of formyl-CoA during peroxisomal α-oxidation of 3-methyl-branched fatty acids. FEBS Lett 407: 197-200.
28. Dacremont G, Cocquyt G, Vincent G (1995) Measurement of very long-chain fatty acids, phytanic acid and pristanic acid in plasma and cultured fibroblasts by gas chromatography. J Inher Metab Dis 18 (supplement 1): 76-83.
29. Danks DM, Tippett P, Adams C, Campbell P (1975) Cerebro-hepato-renal syndrome of Zell-weger. J Pediatr 86: 382-387.
30. Dieuaide-Noubhani M, Novikov D, Baumgart E et al (1996) Further characterization of the peroxisomal 3-hydroxy-acyl-CoA dehydrogenases and evidence that fatty acids and the bile acids di- and trihydroxycoprostanic acid are metabolized by separate multifunctional proteins. Eur J Biochem 240: 660-666.
31. Dieuaide-Noubhani M, Novikov D, Vandekerckhove J, Veldhoven PP van, Mannaerts GP (1997) Identification and characterization of the 2-enoyl-CoA hydratases involved in peroxisomal β-oxidation in rat liver. Biochem J 321: 253-259.
32. Dodt G, Braverman N, Wong C et al (1995) Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nature Genet 9: 115-125.
33. Draye JP, van Hoof F, de Hoffmann E, Vamecq J (1987) Peroxisomal oxidation of L-2-hydroxyphytanic acid in rat kidney cortex. Eur J Biochem 167: 573-578.
34. Duncan WRH, Garton GA (1963) Plasma lipids of the cow during pregnancy and lactation. Biochem J 89: 414-419.
35. Eldjarn L, Try K, Stokke O (1966) The existence of an alternative pathway for the degradation of branched-chain fatty acids, and its failure in heredopathia atactica polyneuritiformis (Refsum's disease). Biochim Biophys Acta 116: 395-397.
36. Espeel M, Mandel H, Poggi F et al (1995) Peroxisome mosaicism in the livers of peroxisomal deficiency patients. Hepatology 22: 497-504.
37. Farrell SO, Fiol CJ, Reddy JK, Bieber LL (1984) Properties of the purified carnitine acyltransferases of mouse liver peroxisomes. J Biol Chem 259: 13089-13095.
38. Fournier BHS (1996) Human peroxisomal acyl-CoA oxidase deficiency. Thesis, University of Utrecht, The Netherlands.
39. Giros M, Roels F, Prats J (1996) Long survival in a case of peroxisomal biogenesis disorder with peroxisome mosaicisum in the liver. Ann New York Acad Sci 804: 747-749.
40. Goldfisher S, Moore CL, Johnson AB (1973) Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 182: 63.
41. Goldfisher S, Collins J, Rapin I, et al (1986) Pseudo-Zellweger Syndrome: deficiencies in several peroxisomal oxidative activities. J Pediatr 108: 25-32.
42. Gray RGF, Green A, Schutgens RBH, Wanders RJA, Farnson PA, Kennedy CR (1990) Antenatal diagnosis of rhizomelic chondrodysplasia punctata in the second trimester. J Inher Metab Dis 13: 380-382.
43. Gray RGF, Green A, Chapman S, McKeown C, Schutgens RBH, Wanders RJA (1992) Rhizomelic chondrodysplasia punctata - a new clinical variant. J Inher Metab Dis 15: 931-932.
44. Greter J, Linstedt S, Steen G (1983) 2,6-Dimethyloctanedioic acid - a metabolite of phytanic acid in Refsum's disease. Clin Chem 29: 434-437.
45. Hansen RP (1966) Phytanic acid and other branched chain fatty acid constituents of bovine rumen bacteria. J Dairy Res 33: 333-342.
46. Hansen RP (1980) Phytol: its metabolic products and their distribution. A review. New Zealand J Sci 23: 259-275.
47. Hansen RP, Morrison JD (1964) The isolation of identification of 2,6,10,14-tetramethyl-pentadecanoic acid from butterfat. Biochem J 93: 225-228.
48. Hansen RP, Shorland FB (1951) The branched chain fatty acids of butterfat II. Isolation of a multibranched C20 saturated fatty acid fraction. Biochem J 50: 358-360.
49. Hansen RP, Shorland FB, Morrison JD (1965) Identification of a C20 multibranched fatty acid from butterfat as 3,7,11,15-tetramethylhexadecanoic acid. J Dairy Res 32: 21-26.
50. Heikoop JC, van Roermund, CWT, Just WW et al (1990) Rhizomelic chondrodysplasia punctata, deficiency of 3-oxoacyl-coenzyme A thiolase in peroxisomes and impaired processing of the enzyme. J Clin Invest 86: 126-130.
51. Heikoop JC, Wanders RJA, Strijland A, Purvis R, Schutgens RBH, Tager JM (1992) Genetic and biochemical heterogeneity in patients with the rhizomelic form of chondrodysplasia punctata - a complementation study. Hum Genet 89: 439-444.
52. Herndon JH Jr, Steinberg D, Uhlendorf BW, Fales HM (1969) Refsum's disease: characterization of the enzyme defect in cell culture. J Clin Invest 48: 1017-1032.
53. Heymans HSA, van den Bosch H, Schutgens RBH, et al (1984) Deficiency of plasmalogens in the cerebro-hepato-renal (Zellweger) syndrome. Eur J Pediatr 142: 10-15.
54. Hoefler G, Hoefler S, Watkins PA et al (1988a) Biochemical abnormalities in rhizomelic chondrodysplasia puncta. J Pediatr 112: 726-733.
55. Hoefler S, Hoefler G, Moser AB, Watkins PA, Chen WW, Moser HW (1988b) Prenatal diagnosis of rhizomelic chondrodysplasia punctata. Prenat Diagn 8: 571-576.
56. Huang S, van Veldhoven PP, Vanhoutte F, Parmentier G, Eyssen HJ, Mannaerts GP (1992) α-Oxidation of 3-methyl-substituted fatty acids in rat liver. Arch Biochem Biophys 296: 214-223.
57. Hutton D, Steinberg D (1973) Identification of propionate as a degradation product of phytanic acid oxidation in rat and human tissues. J Biol Chem 218: 6871-6875.
58. Jakobs BS, Wanders RJA (1995) Fatty acid β-oxidation in peroxisomes and mitochondria: the first, unequivocal evidence for the involvement of carnitine in shuttling propionyl-CoA from peroxisomes to mitochondria. Biochem Biophys Res Commun 213: 1035-1041.
59. Jansen GA, Wanders RJA, de Groot CJ, Moser HW, Mihalik SJ, Watkins PA (1996a) Phytanoyl-CoA hydroxylase deficiency: discovery of the long-sought enzyme defect in Refsum disease. N Eng J Med 337: 133-134.
60. Jansen GA, Mihalik SJ, Watkins P et al (1996b) Phytanoyl-CoA hydroxylase is present in human liver, located in peroxisomes, and deficient in Zellweger syndrome: direct, unequivocal evidence for the new, revised pathway of phytanic acid α-oxidation in human. Biochem Biophys Res Commun 229: 205-210.
61. Jansen GA, Ofman R, Ferdinandusse S et al (1997a) Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nature Genetics 17: 190-193.
62. Jansen GA, Mihalik SJ, Watkins PA, et al (1997b) Phytanoyl-CoA hydroxylase is not only deficient in classical Refsum disease but also in rhizomelic chondrodysplasia punctata. J Inher Metab Dis 20: 444-446.
63. Jiang LL, Kurosawa T, Sota M, Suzuki Y, Hashimoto T (1997) Physiological role of D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein. J Biochem 121: 506-513.
64. Kase BF, Olund J, Sisfontes L (1991) Separation of phytanic acid by high-pressure liquid chromatography : application of the method. Anal Biochem 196: 95-98.
65. Kelley RI, Datta NS, Dobyns WB, et al (1986) Neonatal adrenoleukodystrophy: new cases, biochemical studies and differentiation from Zellweger syndrome and related peroxisomal polydystrophy syndromes. Am J Med Genet 23: 869-901.
66. Kitareewan S, Burka LT, Tomer KB, et al (1996) Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 7: 1153-1166.
67. Klenk E, Kahlke W (1963) Über das Vorkommen der 3,7,11,15-tetramethylhexadecansäure (Phytansäure) in den cholesterinestern und andere Lipidfractionen der Organe bei einem Krankheitsfall unbekannter Genese (Verdacht auf Hetedopathia Atactica Polyneuritiformis [Refsum Syndrome]). Hoppe Zeilers Z Physiol Chem 333: 133-139.
68. Kremer GJ (1966) Über das Vorkommen der 3,7,11,15-Tetramethylhexadecan-säure (Phytansäure) beim Menschen. Z Physiol Chem 334: 227-231.
69. Laurell S (1968) Separation and characterization of phytanic acid-containing plasma triglycerides from a patient with Refsum's disease. Biochim Biophys Acta 152: 75-79.
70. Lazarow PB, De Duve C (1976) A fatty acyl-CoA oxidizing system in rat liver peroxisomes: enhancement of clofibrate, a hypolipidemic drug. Proc Natl Acad Sci USA 73: 2043-2046.
71. Lazarow PB, Black V, Shio H, et al (1985) Zellweger syndrome: biochemical and morphological studies on two patients treated with clofibrate. Pediatr Res 19: 1356-1364.
72. Lazarow PB, Moser HW (1995) Disorders of peroxisome biogenesis. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 2287-2324.
73. Lemotte PK, Keidel S, Apfel CM (1996) Phytanic acid is a retinoid receptor ligand. Eur J Biochem 236: 328-333.
74. Malmendier CL, Jonniaux G, Voet W, van den Bergen CJ (1974) Fatty acid composition of tissues in Refsum's disease (heredopathia actactica polyneuritiformis): estimation of total phytanic acid accumulation. Biomedicine 20: 398-407.
75. Mandel H, Berant M, Aizin A, et al (1992) Zellweger-like phenotype in two siblings: a defect in peroxisomal β-oxidation with elevated very long chain fatty acids but normal bile acids. J Inher Metab Dis 15: 381-384.
76. Mandel H, Espeel M, Roels F, et al (1994) A new type of peroxisomal disorder with variable expression in liver and fibroblasts. J Pediatr 125: 549-555.
77. Mannaerts GP, van Veldhoven PP (1995) Functional aspects of peroxisomal-β-oxidation: an overview. In Wanders RJA, Schutgens RBH, Tabak HF, eds. Functions and Biogenesis of Peroxisomes in Relation to Human Disease. KNAW, Amsterdam, 1-27.
78. Martinez M, Pineda M, Vidal R, Cinill J, Martin B (1993) Docosahexaenoic acid - a new therapeutic approach to peroxisomal-disorder patients; experience with 2 cases. Neurology 43: 1389-1397.
79. McGuinness MC, Moser AB, Poll-The BT, Watkins PA (1993) Complementation analysis of patients with intact peroxisomes and impaired peroxisomal β-oxidation. Biochem Med Metab Biol 49: 228-242.
80. Miayazawa S, Osumi T, Hashimoto T (1980) The presence of a new 3-oxo-acyl-CoA thiolase in rat liver peroxisomes. Eur J Biochem 103: 589-596.
81. Mihalik SJ, Soliman TM, Day RF, Watkins PA (1992) Involvement of both peroxisomes and mitochondria in the α-oxidation of phytanic acid. Prog Clin Biol Res 375: 239-244.
82. Mihalik SJ, Rainville AM, Watkins PA (1995) Phytanic acid α-oxidation in rat liver peroxisomes; production of α-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors. Eur J Biochem 232: 545-551.
83. Mihalik SJ, Morrell JC, Kim D, Sacksteder KA, Watkins PA, Gould SJ (1997) Identification of PAHX, a Refsum disease gene. Nature Genetics 17: 185-189.
84. Mize CE, Steinberg D, Avigan J, Fales HM (1966) A pathway for oxidative degradation of phytanic acid in animals. Biochem Biophys Res Commun 25: 359-365.
85. Mize CE, Herndon JH Jr, Blass JP, et al (1969) Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease. J Clin Invest 48: 1033-1040.
86. Moser AB, Rasmussen M, Naidu S, et al (1995a) Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr 127: 13-22.
87. Moser HW, Smith KD, Moser AB (1995b) X-linked adrenoleukodystrophy. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 2325-2350.
88. Motley AM, Hettema EH, Hogenhout EM, et al (1997) Rhizomelic chondrodysplasia punctata is a peroxisomal targetting disease caused by a non-functional PTS2 receptor. Nature Genetics 15: 377-380.
89. Murad S, Chen RHK, Kishimoto Y (1977) α-Hydroxylation of fatty acids in brain. J Biol Chem 252: 5206-5210.
90. Muralidharan VB, Kishimoto Y (1984) Phytanic acid α-oxidation in rat liver; requirement of a cytosolic cofactor. J Biol Chem 259: 13021-13026.
91. Nadal N, Rolland MO, Tranchant C, et al (1995) Localization of Refsum disease with increased pipecolic acidaemia to chromsome 10p by heterozygosity mapping and carrier testing in a single nuclear family. Hum Mol Genet 4: 1963-1966.
92. Novikov DK Vanhove GF, Carchon H, et al (1994) Peroxisomal β-oxidation. Purification of four novel 3-hydroxyacyl-CoA dehydrogenases from rat liver peroxisomes. J Biol Chem 269: 27125-27135.
93. Ofman R, Jansen GA, Muijsers TO, Wanders RJA (1997) Purification of phytanoyl-CoA hydroxylase from rat liver peroxisomes and characterization of the enzyme protein. J Inher Metab Dis 20 (Supplement 1): 870.
94. Pahan K, Singh I (1993) Intraorganellar localization of CoASH-independent phytanic acid oxidation in human liver peroxisomes. FEBS Lett 333: 154-158.
95. Pahan K, Singh I (1995) Phytanic acid oxidation: topographical localization of phytanoyl-CoA ligase and transport of phytanic acid into human peroxisomes. J Lipid Res 36: 986-997.
96. Patton S, Benson AA (1966) Phytol metabolism in bovine. Biochim Biophys Acta 125: 22-32.
97. Poll-The BT (1988) Genetic peroxisomal disorders. Thesis, University of Amsterdam.
98. Poll-The BT, Saudubray JM, Ogier H, et al (1986) Infantile Refsum's disease: an inherited peroxisomal disorder: comparison with Zellweger syndrome and neonatal adrenoleukodystrophy. Eur J Pediatr 147: 477-483.
99. Poll-The BT, Skjeldal OH, Stokke O, Poulos A, Demaugre F, Saudubray JM (1989) Phytanic acid α-oxidation and complementation analysis of classical Refsum and peroxisomal disorders. Hum Genet 81: 175-181.
100. Poll-The BT, Maroteaux P, Narcy C, et al (1991) A new type of chondrodysplasia punctata associated with peroxisomal dysfunction. J Inher Metab Dis 14: 361-363.
101. Portsteffen H, Beyer A, Becker E, Epplen C, Pawlak A, Kunau WH, Dodt G (1997) Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. Nature Genet 17: 449-452.
102. Poulos A, Sharp P, Fellenberg AJ, Johnson DW (1988a) Accumulation of pristanic acid (2,6, 10,14-tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction. Eur J Pediatr 147: 143-147.
103. Poulos A, Sheffield L, Sharp P, et al (1988b) Rhizomelic chondrodysplasia punctata: clinical, pathologic, and biochemical findings in two patients. J Pediatr 113: 685-690.
104. Poulos A, Sharp P, Singh H, Johnson DW, Carey WF, Easton C (1993) Formic acid is a product of the α-oxidation of fatty acids by human skin fibroblasts: deficiency of formic acid production in peroxisome deficient fibroblasts. Biochem J 292: 457-461.
105. Purdue PE, Zhang JW, Skoneczny M, Lazarow PB (1997) Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue to the yeast PTS2 receptor. Nature Genetics 15: 381-384.
106. Qin YM, Poutanen MH, Helander HM, et al (1997) Peroxisomal multifunctional enzyme of β-oxidation metabolizing D-3-hydroxyacyl-CoA esters in rat liver: molecular cloning, expression and characterization. Biochem J 321: 21-28.
107. Refsum S (1946) Heredopathia acatica polyneuritiformis. Acta Psychiatr Scand Suppl 38: 9.
108. Reuber BE, Germain-Lee E, Collins CS et al (1997) Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nature Genet 17: 445-448.
109. Santos MJ, Ojeda MJ, Garrido J, Leighton F (1985) Peroxisomal organization in normal and cerebrohepatorenal (Zellweger) syndrome fibroblasts. Proc Natl Acad Sci USA 82: 6556-6560.
110. Santos MJ, Imanaka T, Shio H, Small GH, Lazarow PB (1988) Peroxisomal membrane ghosts in Zellweger syndrome - aberrant organelle assembly. Science 239: 1536-1538.
111. Schmitz W, Albers C, Fingerhut R, Conzelmann E (1995) Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 231: 815-822.
112. Schram AW, Goldfisher S, van Roermund CWT et al (1987) Human peroxisomal 3-oxo-acyl-CoA thiolase deficiency. Proc Natl Acad Sci USA 84: 2494-2496.
113. Schutgens RB, Schrakamp G, Wanders, RJA, Heymans HSA, Tager JM, van den Bosch H (1989) Prenatal and perinatal diagnosis of peroxisomal disorders. J Inher Metab Dis 12 (supplement 1): 118-134.
114. Schutgens RBH, Wanders RJA, Jakobs C, et al (1994) A new variant of Zellweger syndrome with normal peroxisomal functions in cultured fibroblasts. J Inher Metab Dis 17: 319-322.
115. Scotto J, Hadchouel M, Odievre M, et al (1982) Infantile phytanic acid storage disease, a possible variant of Refsum's disease: three cases, including ultrastructural studies of liver. J Inher Metab Dis 5: 83-90.
116. Shimozawa N, Tsukamoto T, Suzuki Y, Orii T, Shirayoshi Y, Mori T, Fujiki Y (1992) A human gene responsible for Zellweger syndrome that affects peroxisome assembly. Science 255: 1132-1134.
117. Siegmund JB, Meier H, Hoppmann I, Gutsche HU (1995) Cascade filtration in Refsum's disease. Nephrol Dial Transplant 10: 117-119.
118. Singh I, Lazo O, Kalipada P, Singh AK (1992) Phytanic acid α-oxidation in human cultured skin fibroblasts. Biochim Biophys Acta 1180: 221-224.
119. Singh I, Pahan K, Dhaunsi GS, Lazo O, Ozand P (1993) Phytanic acid α-oxidation. Differential subcellar localization in rat and human tissues and its inhibition by Nycodenz. J Biol Chem 268: 9972-9997.
120. Skjeldal OH, Stokke O (1987) The subcellular localization of phytanic acid oxidase in rat liver. Biochim Biophys Acta 921: 38-42.
121. Skjeldal OH, Stokke O (1988) Evidence against α-hydroxyphytanic acid as an intermediate in the metabolism of phytanic acid. Scand J Clin Lab Invest 48: 97-102.
122. Slawecki ML, Dodt G, Steinberg S, Moser AB, Moser HW, Gould SJ (1995) Identification of three distinct peroxisomal protein import defects in patients with peroxisome biogenesis disorders. J Cell Sci 108: 1817-1828.
123. Smeitink JAM, Beemer FA, Espeel M, et al (1992) Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inker Metab Dis 15: 377-380.
124. Sonneveld W, Haverkamp-Begemann P, van Geers G, et al (1962) 3,7,11,15-Tetramethylhexadecanoic acid, a constituent of butterfat. J Lipid Res 3: 351-355.
125. Steinberg D (1995) Refsum disease. In Scriver CR, Beaudet AL, Sly WS and Valle D, eds. The Metabolic and Molecular Bases of Inherited Metabolic Disorders. McGraw-Hill, New York, 2351-2369.
126. Steinberg D, Mize CE, Avigan J, et al (1967a) Studies on the metabolic error in Refsum's disease. J Clin Invest 46: 313-322.
127. Steinberg D, Herndon JH Jr, Uhlendorf BW, Mize CE, Avigan J, Milne GWA (1967b) Refsum's disease. Nature of the enzyme defect. Science 156: 1740-1742.
128. Steinberg D, Vroom FQ, Engel WK, Cammermeyer J, Mize CE, Avigan J (1967c) Refsum's disease - a recently characterized lipidosis involving the nervous system, Ann Intern Med 66: 365-395.
129. Steinberg SJ, Fensom AH (1996) Complementation analysis in patients with the clinical phenotype of a generalized peroxisomal disorder. J Med Genet 33: 295-299.
130. Stokke O (1967) α-Oxidation of fatty acids in various mammals, and a phytanic acid feeding experiment in an animal with a low α-oxidation capacity. Scand J Lab Clin Invest 20: 305.
131. Suzuki Y, Shimozawa N, Yajima S, et al (1994) Novel subtype of peroxisomal acyl-CoA oxidase deficiency and bifunctional enzyme deficiency with detectable enzyme protein: identification by means of complementation analysis. Am J Hum Genet 54: 36-43.
132. Suzuki Y, Jiang LL, Souri M, et al (1997) D-2-Hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency: a newly identified peroxisomal disorder. Am J Hum Genet 61: 1162-1163.
133. ten Brink HJ, Stellaard F, Jakobs C (1990) In vivo use of stable isotopes in the study of phytanic acid metabolism. In Chapman TE, Berger R, Reyngoud DJ, Okken A, eds. Stable Isotopes in Paediatric, Nutritional and Metabolic Research, Andover: Intercepr, 257-262.
134. ten Brink HJ, Stellaard F, van den Heuvel CMM et al (1992a) Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography. J Lipid Res 33: 41-47.
135. ten Brink HJ, Schor DSM, Kok RM, Poll-The BT, Wanders RJA, Jakobs C (1992b) Phytanic acid α-oxidation: presence of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders. J Lipid Res 33: 1449-1457.
136. ten Brink HJ, Schor DSM, Kok RM, et al (1992c) In vivo study of phytanic acid α-oxidation in classical Refsum's disease and chondrodysplasia punctata. Pediatr Res 32: 566-570.
137. Toyama Y (1923) Über einen gesättigten Kohlenwasserstoff aus den Haifischleberölen. Chemische Umschau 29/30: 181-187.
138. Tranchant C, Aubourg P, Mohr M, Rocchiccioli F, Zaenker Ch, Warter JM (1993) A new peroxisomal disease with impaired phytanic acid and pipecolic acid oxidation. Neurology 43: 2044-2048.
139. Trijbels JMF, Monnens LHA, Bakkeren JAJM, van Raay-Selten AHJ, Corstiaensen JMB (1979) Biochemical studies in the cerebro-hepato-renal syndrome of Zellweger: a disturbance in the metabolism of pipecolic acid. J Inher Metab Dis 2: 39-42.
140. Tsai S-C, Herndon JH Jr, Uhlendorf BW, Fales HM, Mize CE (1967) The formation of α-hydroxyphytanic acid from phytanic acid in mammalian tissues. Biochem Biophys Res Commun 28: 571-577.
141. Tsai SC, Avigan J, Steinberg D (1969) Studies on the α-oxidation of phytanic acid by rat liver mitochondria. J Biol Chem 244: 2682-2692.
142. Vamecq J, Draye JP (1988) The enzymatic and mass spectrometric identification of 2-oxophytanic acid, a product of the peroxisomal oxidation of L-2-hydroxyphytanic acid. Biomed Environ Mass Spectrum 15: 345-351.
143. Van Grunsven EG, van Roermund CWT, Denis S, Wanders RJA (1997a) Complementation analysis of fibroblasts from peroxisomal fatty acid oxidation deficient patients shows high frequency of bifunctional enzyme deficiency plus intragenic complementation: unequivocal evidence for differential defects in the same enzyme protein. Biochem Biophys Res Commun 235: 176-179.
144. Van Grunsven I, van Roermund CWT, Denis S, et al (1997b) Peroxisomal multifunctional protein 2 (pMFP2) deficiency: a new peroxisomal disorder and resolution of its molecular basis. J Inher Metab Dis 20 (supplement 1): 72.
145. Vanhove G, van Veldhoven PP, Vanhoutte F, Parmentier G, Eyssen HJ, Mannaerts GP (1991) Mitochondrial and peroxisomal β-oxidation of the branched chain fatty acid 2-methylpalmitate in rat liver. J Biol Chem 266: 24670-24675.
146. Vanhove GF, van Veldhoven PP, Fransen M, et al (1993) The CoA-esters of 2-methyl-branched chain fatty acids and the bile acid intermediates di- and trihydroxycopristanic acids are oxidized by one single peroxisomal branched-chain acyl-CoA oxidase in human liver and kidney. J Biol Chem 268: 10335-10344.
147. van Veldhoven PP, Vanhove G, Vanhoutte F, et al (1991) Identification and purification of a peroxisomal branched chain fatty acyl-CoA oxidase. J Biol Chem 266: 24676-24683.
148. Verhoeven NM, Kulik W, van den Heuvel CMM, et al (1995) Pre- and postnatal diagnosis of peroxisomal disorders using stable isotope dilution gas chromatography mass spectrometry. J Inher Metab Dis 18 (Supplement 1): 45-60.
149. Verhoeven NM, Wanders RJA, Schor DSM, Jansen GA, Jakobs C (1997a) Phytanic acid α-oxidation: decarboxylation of 2-hydroxyphytanoyl-CoA to pristanic acid in human liver. J Lipid Res 38: 2062-2070.
150. Verhoeven NM, Schor DSM, ten Brink HJ, Wanders RJA, Jakobs C (1997b) Resolution of the phytanic acid α-oxidation pathway: identification of pristanal as the product of the decarboxylation of 2-hydroxyphytanoyl-CoA. Biochem Biophys Res Commun 237: 33-36.
151. Verhoeven NM, Schor DSM, Previs SF, Brunengraber H, Jakobs C (1997c) Stable isotope studies of phytanic acid α-oxidation: in vivo production of formic acid. Eur J Pediatr 156 (supplement 1): S83-S87.
152. Verhoeven NM, Schor DSM, Jansen GA, et al (1997d) Formation of 2,3-pristenic acid and 3-hydroxypristanic acid from pristanic acid in human liver. J Inher Metab Dis 20: 441-443.
153. Verhoeven NM, Schor DSM, Roe CR, Wanders RJA, Jakobs C (1997e) Phytanic acid α-oxidation in peroxisomal disorders: studies in cultured human fibroblasts. Biochim Biophys Acta 1361: 281-286.
154. Verhoeven NM, Schor DSM, Roe CR, Wanders RJA, Jakobs C (1998a) Phytanic acid β-oxidation in peroxisomal disorders: studies in cultured human fibroblasts. Biochim Biophys Acta 1391: 351-356.
155. Verhoeven NM, Roe DS, Kok RM, Wanders RJA, Jakobs C, Roe CR (1998b) Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J Lipid Res 39: 66-74.
156. Wanders RJA, Romeijn GJ (1997) Cholesterol synthesis, peroxisomes and peroxisomal disorders: differential deficiency of mevalonate kinase and phosphomevalonate kinase in Zell-weger syndrome and RCDP. J Inher Metab Dis 20 (supplement 1): 69.
157. Wanders RJA, van Roermund CWT (1993) Studies on phytanic acid α-oxidation in rat liver and cultured human fibroblasts. Biochim Biophys Acta 1167: 345-350.
158. Wanders RJA, Schutgens RBH, Heymans HSA, et al (1987) Biochemical analyses in peroxisomal disorders. In HD Fahimi and H Sies, eds. Peroxisomes in Biology and Medicine. Heidelberg: Springer Verlag, 341-352.
159. Wanders RJA, van Roermund CWT, Schelen A, et al (1990) A bifunctional protein with deficient enzymic activity: identification of a new peroxisomal disorder using novel methods to measure the peroxisomal beta-oxidation enzyme activities. J Inher Metab Dis 13: 375-379.
160. Wanders RJA, van Roermund CWT, Jakobs C, ten Brink HJ (1991) Identification of pristanoyl-CoA oxidase and phytanic acid decarboxylation in peroxisomes and mitochondria from human liver: implications for Zellweger syndrome. J Inher Metab Dis 14: 349-352.
161. Wanders RJA, Denis S, van Roermund CWT, Jakobs C, ten Brink HJ (1992a) Characteristics and subcellular localization of pristanoyl-CoA synthetase in rat liver. Biochim Biophys Acta 1125: 274-279.
162. Wanders RJA, Schumacher H, Heikoop J, Schutgens RBH, Tager JM (1992b) Human dihydroxyacetonephosphate acyltransferase deficiency: a new peroxisomal disorder. J Inher Metab Dis 15: 389-391.
163. Wanders RJA, van Roermund CWT, Schor DSM, ten Brink HJ, Jakobs C (1994a) 2-Hydroxyphytanic acid oxidase activity in rat liver and its deficiency in the Zellweger syndrome. Biochim Biophys Acta 1227: 177-182.
164. Wanders RJA, Decker C, Horvath A et al (1994b) Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisomal disorder. J Inher Metab Dis 17: 315-318.
165. Wanders RJA, Barth PG, Schutgens RBH, Heymans HSA (1996) Peroxisomal disorders: post- and prenatal diagnosis based on a new classification with flowcharts. Int Pediat 11: 203-214.
166. Wanders RJA, Denis S, Wouters F, Wirtz KWA, Seedorf U (1997) Sterol carrier protein X (SCPx) is a peroxisomal branched-chain β-ketothiolase specifically reacting with 3-oxopristanoyl-CoA: a new, unique role for SCPx in branched-chain fatty acid metabolism in peroxisomes. Biochem Biophys Res Commun 236: 565-569.
167. Watkins PA, Chen WW, Harris CJ, et al (1989) Peroxisomal bifunctional enzyme deficiency. J Clin Invest 83: 771-777.
168. Watkins PA, Mihalik SJ, Skjeldal OH (1990) Mitochondrial oxidation of phytanic acid in human and monkey liver: implication that Refsum's disease is not a peroxisomal disorder. Biochem Biophys Res Commun 167: 580-586.
169. Watkins PA, Howard AE, Mihalik SJ (1994) Phytanic acid must be activated to phytanoyl-CoA prior to its α-oxidation in rat liver peroxisomes. Biochim Biophys Acta 1214: 288-294.
170. Watkins PA, Howard AE, Gould SJ, Avigan J, Mihalik SJ (1996) Phytanic acid oxidation in rat liver peroxisomes is catalyzed by long-chain acyl-CoA synthetase. J Lipid Res 37: 2288-2295.
171. Watkins PA, McGuinness MC, Raymond GV et al (1995) Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies. Ann Neurol 38: 472-477.
172. Willstätter R, Mayer EW, Huni E (1911) Untersuchungen über Chlorophyll XII Über Phytol I. Liebigs Ann 378: 73-152.
173. Yahraus T, Braverman N, Dodt G et al (1996) The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J 15: 2914-2923.